FDA Commissioner Outlines Ambitious Vision for Breakthrough Treatments

FDA commissioner Marty Makary this week shared an expansive vision for future medical breakthroughs, telling agency staff (audio link – begins at 47:28 mark) he hopes to see transformative treatments — and potentially cures — across a range of serious diseases in the coming years

Speaking about long-term priorities, Makary pointed to Type 1 diabetes as a key target, saying he would like to see “a cure or powerful treatment” emerge. He emphasized that the agency is actively engaging with scientists to track early-stage innovations and position the FDA to help guide promising therapies through development. “If there’s something that looks promising in early studies, we want to be very involved and watch that technology and usher it through,” Makary said.

Beyond diabetes, Makary highlighted amyotrophic lateral sclerosis (aka Lou Gehrig’s disease) as another area where he believes meaningful progress is within reach. He expressed optimism that new treatments could move beyond slowing disease progression to halting or even reversing neurodegenerative conditions within the next few years.

Makary also underscored advances in oncology, particularly the emergence of immunotherapies such as PD-1 inhibitors. He noted that in certain cancers — including some metastatic and gastrointestinal tumors with microsatellite instability — these therapies have led to complete tumor elimination in early studies. “In the case of some rectal cancers, surgeons are seeing these tumors disappear over the course of treatment,” he said, adding that such outcomes could spare patients from surgery, chemotherapy, or radiation while reducing long-term complications and healthcare costs.

Looking more broadly, Makary said he hopes to see breakthroughs across additional conditions, including pediatric kidney disease and autoimmune disorders, arguing that the scientific community is “on the brink of some major discovery.”

Among preventive innovations, Makary pointed to the possibility of a universal influenza vaccine targeting Influenza. He criticized current seasonal vaccine strategies as imprecise due to the virus’s high mutation rate and said a longer-lasting shot capable of protecting against multiple strains — including those not yet circulating — could significantly reduce annual mortality.

Finally, Makary suggested that advances in the biology of aging may soon yield powerful new treatments, raising the prospect of extending human lifespan and healthspan.

While aging-related therapies seem very intriguing, FDA does not currently classify aging as a disease, a regulatory gap that longevity scientists argue is hindering the development and approval of therapies aimed at slowing the biological aging process. Because FDA approval requires targeting a defined medical condition, researchers must instead test potential anti-aging drugs against individual diseases like Alzheimer's disease or Type 2 diabetes, rather than addressing aging itself — the primary driver behind many chronic illnesses.

Scientists contend this FDA framework is outdated, given advances in geroscience, and point to efforts like the TAME trial, which is testing whether the diabetes drug Metformin can delay multiple age-related diseases simultaneously, potentially establishing aging as a viable clinical target, according to a 4/3 altitudesmagazine.com article by Dr. Eliot Soren Vance. Advocates argue that formally recognizing aging as a treatable condition could unlock new drug development pathways, expand insurance coverage for preventive therapies, and reduce the long-term burden of chronic disease. However, some critics warn that such a shift could medicalize a universal human process, strain healthcare resources, and face major scientific hurdles, including defining measurable clinical endpoints for aging, according to Vance.

Taken together, his remarks signal an FDA leadership agenda focused not only on accelerating drug approvals, but also on proactively supporting cutting-edge science that could redefine treatment paradigms across multiple disease areas.